Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bio-Techne Corp (NQ: TECH )

71.28 +0.23 (+0.32%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bio-Techne Corp

< Previous 1 2 3 4 5 Next >
Stocks That Hit 52-Week Lows On Wednesday
  During Wednesday's session, 265 companies made new 52-week lows. 
Via Benzinga
NexImmune Price Target Cut By 75%, Plus Wells Fargo Lowers PT Price Target On These Stocks
Raymond James cut the price target for NexImmune, Inc. (NASDAQ: NEXI) from $12 to $3. NexImmune shares rose 2.4% to $1.29 in pre-market trading. 
Via Benzinga
Recap: Bio-Techne Q4 Earnings
  Bio-Techne (NASDAQ:TECH) reported its Q4 earnings results on Thursday, August 4, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Recap: Bio-Techne Q3 Earnings
Bio-Techne (NASDAQ:TECH) reported its Q3 earnings results on Wednesday, May 4, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022
Upgrades 
Via Benzinga
Tackling Recurring Health Conditions Offers Hope to Patients
Palm Beach, FL – June 21, 2022 – FinancialNewsMedia.com News Commentary – Being diagnosed with a health condition can often come as a shock but finding out it can recur is a double blow, particularly... 
Via FinancialNewsMedia
Bio-Techne Clocks 17% Organic Revenue Growth In Q2, Announces $400M Share Buyback
Bio-Techne Corporation (NASDAQ: TECH) has posted Q2 FY22 s 
Via Benzinga
Earnings Scheduled For November 2, 2021
Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion. •... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 951 companies hit new 52-week lows. 
Via Benzinga
7 Defensive Growth Stocks to Buy for a Shaky Market
These are the best defensive growth stocks to invest in now. Each of these can make great investments if/when the market sours. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022
Via Benzinga
7 Superior Stocks That Smart Investors Will Buy on the Dip
The recent sell-off presents long-term investors with many robust stocks to buy on the dip. These seven provide a start. 
Via InvestorPlace
10 Biggest Price Target Changes For Wednesday
Keybanc lifted the price target for Alphabet Inc. (NASDAQ: GOOGL) from $3,090 to $3,400. Alphabet shares surged 11% to $3,055.00 in pre-market trading. 
Via Benzinga
The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Here's How Much You Would Have Made Owning Bio-Techne Stock In The Last 5 Years
Bio-Techne (NASDAQ:TECH) has outperformed the market over the past 5 years by 17.84% on an annualized basis. Buying $1,000.00 In TECH: 5 years ago, an investor could have... 
Via Benzinga
Bio-Techne Corporation (TECH) Q1 2022 Earnings Call Transcript
TECH earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares... 
Via Benzinga
Exposures COVID-19
Bio-Techne's Earnings: A Preview
Bio-Techne (NASDAQ:TECH) is set to give its latest quarterly earnings report on Tuesday, 2021-11-02. Here's what investors need to know before the announcement. Analysts estimate... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Rise Ahead Of Economic Data; Crude Oil Gains 1%
Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones dipped nearly 300 points in the previous week. Investors are awaiting earnings... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC)... 
Via Benzinga
Director Of Bio-Techne Trades $4.80 Million In Company Stock
Randolph C Steer, Director at Bio-Techne (NASDAQ:TECH), made a large buy and sell of company shares on September 7, according to a new SEC filing. What Happened: A Form 4 filing... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
CFO Of Bio-Techne Trades $6.14 Million In Company Stock
James Hippel, Chief Financial Officer at Bio-Techne (NASDAQ:TECH), made a large buy and sell of company shares on September 2, according to a new SEC filing. What Happened: A Form... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13) Abbott Laboratories (NYSE... 
Via Benzinga
Exposures COVID-19
Bio-Techne Corporation (TECH) Q4 2021 Earnings Call Transcript
TECH earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Stocks That Hit 52-Week Highs On Thursday
On Thursday morning, 159 companies achieved new highs for the year. Things to Consider: The largest company by market cap to break to a new 52-week high was ASML... 
Via Benzinga
The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Abbott Laboratories (NYSE:... 
Via Benzinga
Recap: Bio-Techne Q4 Earnings
Shares of Bio-Techne (NASDAQ:TECH) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share were up 87.00% over the past year to $1.87,... 
Via Benzinga
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.